Ann Dermatol.  2019 Feb;31(1):90-92. 10.5021/ad.2019.31.1.90.

Incidence of Topical Tacrolimus Adverse Effects in Chronic Skin Disease

• Park HJ
• Gwak MJ
• Jeong KH
• Lee MH
• Shin MK

• KMID: 2430810
• DOI: http://doi.org/10.5021/ad.2019.31.1.90

Abstract

No abstract available.

MeSH Terms

Incidence*
Skin Diseases*
Skin*
Tacrolimus*
Tacrolimus

Figure

• 

  Fig. 1 (A) Adverse effect (AE) incidence rates (%). AE incidence rates are significantly different between atopic dermatitis and rosacea groups (marked with *p=0.033). Patients with vitiligo showed statistically lower AE rates compared to all other subgroups (marked with †p=0.037 with atopic dermatitis, p=0.010 with irritated contact dermatitis, p=0.006 with seborrheic dermatitis, p=0.000 with rosacea subgroup). (B) Side effects and application site. There was no correlation between severe side effects or treatment discontinuation with applied site (p=1.000 between severe side effects and applied site, p=1.000 between treatment discontinuation and applied site).

Reference

1. Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology. 2007; 215(Suppl 1):45–54.

2. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol. 2007; 157:861–873. PMID: 17854353.

3. Ständer S, Ständer H, Seeliger S, Luger TA, Steinhoff M. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol. 2007; 156:1020–1026. PMID: 17388925.

4. Powell FC, Corbally N, Powell D. Substance P and rosacea. J Am Acad Dermatol. 1993; 28:132–133.

5. Lim YY, Kim HM, Lee HI, Mun SK, Kim CW, Kim MN, et al. A comparison of neuropeptide expression in skin with allergic contact dermatitis in human and mouse. Int J Dermatol. 2012; 51:939–946. PMID: 22788810.

6. Teresiak-Mikołajczak E, Czarnecka-Operacz M, Jenerowicz D, Silny W. Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus. Postepy Dermatol Alergol. 2013; 30:286–292. PMID: 24353488.

7. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol. 1994; 131:160–165. PMID: 7522512.

8. Falabella R, Barona MI, Echeverri IC, Alzate A. Substance P may play a part during depigmentation in vitiligo. A pilot study. J Eur Acad Dermatol Venereol. 2003; 17:355–356. PMID: 12702089.

9. Hristakieva E, Lazarova R, Lazarov N, Stanimirović A, Shani J. Markers for vitiligo related neuropeptides in human skin nerve fibers. Acta Med Croatica. 2000; 54:53–57. PMID: 11028109.